menu
    • menu
    [{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Almirall"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Hyphens Pharma"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Endo Pharm"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 VLS","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 CKD","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MC2-32","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by MC2 Therapeutics

    Menu

    MC2 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Hyphens Pharma

    Deal Size : $2.7 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

    Details : MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.

    Product Name : Wynzora

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 03, 2024

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Hyphens Pharma

    Deal Size : $2.7 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Endo Pharm

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

    Details : The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.

    Product Name : Wynzora

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 15, 2024

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Endo Pharm

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MC2-32

    Therapeutic Area : Dermatology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Gets Positive FDA Feedback And Updates Expansion Strategy

    Details : MC2-32 (previously RGRN-305) is a small molecule, HSP90 inhibitor. It is being evaluated in the phase II clinical trial studies for the treatment of hidradenitis suppurativa.

    Product Name : MC2-32

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    May 13, 2024

    Lead Product(s) : MC2-32

    Therapeutic Area : Dermatology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MC2-25 VLS

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen...

    Details : MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin.

    Product Name : MC2-25 VLS

    Product Type : Peptide

    Upfront Cash : Inapplicable

    November 23, 2023

    Lead Product(s) : MC2-25 VLS

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MC2-25 CKD

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus T...

    Details : MC2-25, a first-in-class di-peptide drug candidate functioning as an effective isocyanate scavenger, is presently undergoing Phase II clinical trial evaluation for the treatment of Chronic Kidney Disease-associated Pruritus.

    Product Name : MC2-25 CKD

    Product Type : Peptide

    Upfront Cash : Inapplicable

    July 12, 2023

    Lead Product(s) : MC2-25 CKD

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MC2-25

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP

    Details : MC2-25 Cream is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracting the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.

    Product Name : MC2-25

    Product Type : Peptide

    Upfront Cash : Inapplicable

    September 14, 2022

    Lead Product(s) : MC2-25

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MC2-25

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces Breakthrough Discovery With the Potential to Help Millions of People Suffering From...

    Details : MC2-25 CKD-aP is formulated to be highly tolerable, moisturizing, convenient to use and it quickly absorbs into the skin allowing patients to get on with their life and their daily routines.

    Product Name : MC2-25

    Product Type : Peptide

    Upfront Cash : Inapplicable

    January 09, 2022

    Lead Product(s) : MC2-25

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Almirall

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora® Cream for Plaque Psoriasis

    Details : In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

    Product Name : Wynzora

    Product Type : Other Small Molecule

    Upfront Cash : $18.0 million

    February 17, 2021

    Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Almirall

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces FDA Approval of Wynzora® Cream (calcipotriene and betamethasone dipropionate) for ...

    Details : The FDA approval is based on the results of the US Phase 3 clinical trial1 against active comparator Taclonex® Topical Suspension (calcipotriene and betamethasone dipropionate.

    Product Name : Wynzora

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 22, 2020

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed

    MC2 Therapeutics

    Denmark arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora ® Cream

    Details : The MAA is supported by two comprehensive Phase 3 trials1 including a trial conducted in EU evaluating the efficacy and safety of Wynzora® Cream compared to vehicle and active comparator Dovobet/Daivobet® Gel in patients with psoriasis vulgaris.

    Product Name : Wynzora

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    July 16, 2020

    Lead Product(s) : Calcipotriol,Betamethasone

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth